Search the Newsreel

HEALWELL AI Holds Q2 Revenue Steady as Recurring AI Sales and Cash Flow Improve

Why HealWELL AI Inc. stock is sliding today

AIDX: Q2-2026 saw stable revenue, improved cash flow, and a return to net income, with strong recurring sales

Earnings Flash (AIDX.TO) HEALWELL AI Inc. Reports Q2 Revenue C$33.0M, vs. FactSet Est of C$33.2M

20/20 Biolabs to host investor webinar; reports best quarterly cancer-test revenue to date

20/20 Biolabs announced its preliminary Q2 2026 cancer-testing revenue as its best quarter to date and will host an investor webinar on August 5, 2026. The company secured 29 new commercial orders, including large firefighter programs, and is piloting a new product with Giant …

HEALWELL AI will release Q2 results after Aug. 6 close, then host call

HealWELL AI Inc. Class A Revenue Breakdown – TSX:AIDX

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

20/20 BioLabs

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

20/20 BioLabs, an AI-powered blood test company for early detection of cancers and chronic diseases, is advancing its East Asia roll-up strategy by meeting with potential partners in Taipei, Tokyo, and Seoul after participating in BIO Asia-Taiwan. The company aims to expand its mission …

20/20 BioLabs meets potential partners in East Asia

20/20 BioLabs, Inc. (NASDAQ:AIDX) recently met with potential partners in East Asia, including Taipei, Tokyo, and Seoul, as part of an expansion strategy. The company, which develops AI-powered blood tests for early cancer and chronic disease detection, is seeking acquisition, licensing, joint venture, and …

20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX

20/20 Biolabs, Inc. (NASDAQ: AIDX) generated $2.04 million in revenue last year, with its OneTest segment being the top performer, contributing $1.80 million. The United States was the primary source of revenue, accounting for $2.05 million. This article provides a breakdown of the company's …

Rokit Healthcare, US 20/20 BioLabs to Co-Develop AI Multi-Cancer Prediction Platform

Rokit Healthcare and US-based 20/20 BioLabs have partnered to develop an AI-based platform for predicting over 30 cancers and chronic diseases. This expanded collaboration, building on an earlier agreement for chronic kidney disease prediction, aims to integrate various data points like blood tests, genomics, …

20/20 Biolabs Received Notice of Noncompliance

20/20 Biolabs (AIDX) received a noncompliance notice from Nasdaq because its stock traded below $1.00 for 30 consecutive business days. The company has 180 days, until January 13, 2027, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business …

20/20 BioLabs Enters Temporary Standstill Agreement Limiting Series E Preferred Stock Conversions

20/20 BioLabs has entered into a temporary standstill agreement with certain holders of its Series E Preferred Stock. This agreement limits the conversion of these shares into common stock, aiming to manage the company's capital structure. The move suggests a strategic decision to stabilize …

20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history

This article provides a comprehensive overview of 20/20 Biolabs, Inc. (AIDX) stock, including its current price, historical performance, and key financial metrics. It details the company's business in AI-powered blood tests for early cancer detection and chronicles its recent stock depreciation. The report also …

Streeterville Can Convert 20/20 BioLabs Stock Only 10% Above Minimum Price

20/20 BioLabs (Nasdaq: AIDX) has entered a 120-day standstill agreement with Streeterville Capital concerning its Series E Convertible Preferred Stock, effective July 16, 2026. This agreement temporarily prevents Streeterville from converting preferred shares to common stock unless AIDX trades at least 10% above the …

20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

20/20 BioLabs, Inc. (<a href="https://ir.nasdaq.com/institutional/ir.aspx?Sym=AIDX">Nasdaq: AIDX</a>) has entered into a standstill agreement with Streeterville Capital, LLC concerning its Series E Convertible Preferred Stock. This agreement, effective July 16, 2026, temporarily restricts Streeterville Capital from converting Series E Preferred Stock into common stock unless the …

20/20 Biolabs (Nasdaq: AIDX) signs standstill as Nasdaq flags bid-price issue

20/20 Biolabs (AIDX) has entered a 120-day standstill agreement with Streeterville Capital concerning its Series E convertible preferred stock, restricting conversions unless the trading price is significantly higher than Nasdaq's minimum. Concurrently, Nasdaq notified the company of non-compliance with the $1.00 minimum bid price …

20/20 BioLabs pitches OneTest for Medicare as Q2 revenue rises

AIDX Forecast — Price Target — Prediction for 2027

20/20 Biolabs' OneTest™ Selected for Vermont Firefighter Cancer Screening Initiative, Expected to Generate $500,000 in Revenue

HEALWELL lands first Middle East government AI deal in $33.2M quarter

HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold

AIDX: Record 2025 revenue and first positive Adjusted EBITDA mark a successful AI platform transition

20/20 Biolabs (AIDX) Stock Price, News & Analysis

20/20 Biolabs (AIDX) Stock News & Updates

Why We're Not Concerned Yet About Healwell AI Inc.'s (TSE:AIDX) 26% Share Price Plunge

Individual investors are Healwell AI Inc.'s (TSE:AIDX) biggest owners and were hit after market cap dropped CA$28m

Gaithersburg's 20/20 BioLabs files to go public after merger falls through

Strong week for Healwell AI (TSE:AIDX) shareholders doesn't alleviate pain of five-year loss

Analysts Are Updating Their Healwell AI Inc. (TSE:AIDX) Estimates After Its Third-Quarter Results

Healwell AI Inc. (TSE:AIDX) Analysts Are Reducing Their Forecasts For This Year

HEALWELL Reports Record Revenue Growth of 645% in Q2-2025 and Achieves First Quarter of Positive Adjusted EBITDA